The evamist product ramp up continues to improve,however you would have to wonder how long kv can continue as a going concern as they do not appear to have fda sign off yet and they are running out of money.It is my understanding if kv goes broke the evamist distribution goes back to acrux for no cost.Kv paid 150 million for the product and one would anticipate that there would be a number of pharma companies who would like to get their hands on this product and be prepared to pay for the priviledge.
ACR Price at posting:
$1.94 Sentiment: ST Buy Disclosure: Held
